Further experience with norethynodrel in treatment of endometriosis.

H L RIVA, Riva Hl, D M KAWASAKI, Kawasaki Dm, A J MESSINGER, Messinger Aj
Obstetrics and gynecology · 1962 · vol. 19 , pp. 111–7 · PMID:14492548 · W1126058358
article OA: closed CC0 ⤵ 20 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

Norethynodrel therapy led to complete regression in 72% and partial improvement in 18.2% of 132 endometriosis patients, with an 11.8% recurrence rate among those with initial complete regression.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A study involving 156 cases of endometriosis treated with norethynodrel (Enovid) was presented. Diagnosis was established by laparotomy culdoscopy culdoscopy followed by laparotomy or colpotomy. 132 cases were reevaluated following therapy. Complete regression was observed in 72% while an additional 18.2% were at least partially improved. Therapy was of no benefit in less than 9%. The majority of patients were reevaluated after 6 months by culdoscopy and therapy was discontinued. 14 patients were treated for an additional 3-9 months. The average duration of therapy was 6.7 months. Results with therapy following conservative operation were encouraging. Of 9 patients followed to date 8 had been relieved of their symptoms and 6 of these have had repeat culdoscopy with complete regression documented. 2 of these patients became pregnant. In patients who originally showed complete regression and in whom the follow-up had been for 6 months or longer recurrences developed in 11.8%. All patients experienced the side effects of weight gain abdominal fullness and breast enlargement and tenderness. Nausea was uncommon.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Norethynodrel Endometriosis Female Humans Progesterone Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (20)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-14T05:59:39.616318+00:00
License: CC0 · commercial use OK